Eli Lilly’s Alzheimer’s drug receives approval from US FDA
.png)
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzheimer’s now available to US patients.
Earlier this year, the treatment received a recommendation from an independent advisory board despite concerns over certain adverse effects. The board was unanimously in favour of the treatment. This latest milestone for the drug product is a huge achievement for all stakeholders. “This is real progress,” commented Joanne Pike from the Alzheimer’s Assocation. “Having multiple treatment options is the kind of advancement we’ve all been waiting for – all of us who have been touched, even blindsided, by this difficult and devastating disease.”
Donanemab works by clearing a protein called beta-amyloid from the brain, which has been shown to influence the progression of Alzheimer’s. Eli Lilly’s Kisunla differs from the already approved Leqembi from Eisai and Biogen is its finite dosing – patients do not need to continue taking the drug once brain scans are clear of amyloid plaques. However, Eli Lilly’s Kisunla is priced at US$32,000 for a 12-month course while Eisai’s is priced at US$26,500. Analysts attribute this to the non-chronic nature of the treatment compared with Leqembi. “The details of how it will play out in clinical practice are still unclear but I think it will save a lot of money and patient will like it a lot better,” stated Erik Musiek, neurologist at Barnes-Jewish Hospital. “I think that, coupled with monthly dosing, [this] will make this an attractive option.”
A late-stage trial of donanemab demonstrated slowed progression of memory and thinking problems by 29% compared with a placebo. However, like Eisai’s Leqembi, mild brain swelling and brain bleeding were observed in a few patients. The US FDA will be placing boxed safety warnings for potential brain swelling and bleeding on Kisunla, as it has for Leqembi. While Eisai’s product only requires four MRI scans to check for side effects, Kisunla will require five. This may provide some advantage for regions where access to scans is more difficult. Kisunla is expected to be available mostly for patients enrolled in Medicare age 65 and over.
Source:
Eli Lilly Alzheimer’s drug approved by US FDA [Accessed July 4, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-lillys-alzheimers-drug-2024-07-02/
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance